A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

Abstract Poster

Authors

null

Ann W. Silk

Dana-Farber Cancer Institute, Boston, MA

Ann W. Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Renee Spencer, Eugenia Girda, Weichung Shih, Veeraswamy Manne, Marisa Palmeri, Robert Berman, Vlad Coric, Joshua Vieth, Suzie Chen, Janice M. Mehnert, Jyoti Malhotra

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT03229278

Citation

J Clin Oncol 38, 2020 (suppl 5; abstr 79)

Abstract #

79

Poster Bd #

A12

Abstract Disclosures

Similar Posters

First Author: Jermaine Coward

First Author: Sheng Yang

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.

A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.

First Author: Ann W. Silk

First Author: Zhihong Chi